• Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field.
• Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
• Preliminary data are not required.
• Research projects must be innovative, feasible, and supported by a strong rationale.
• Innovation is the most important review criterion.
• Clinical trials are not allowed.

• Maximum funding of $150,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years.

or 

New Investigators:
Independent investigator at or below the level of Assistant Professor (or equivalent); or established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC, thereby bringing his/her expertise to the field.

Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a Principal Investigator of one or more Federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K Awardees are eligible to apply.) 

Must not have received a New Investigator Award previously from any program within the CDMRP.

• Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.
• Preliminary data are expected.
• Impact and Innovation are important review criteria.
• Clinical trials are not allowed.
• New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition or established investigators from other research fields into career in TSC research.
• Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately.

• Maximum funding of $500,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

• Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC.
• Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies.
• Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
• Preclinical studies may be appropriate but must include a clinical component.
• Projects that are exploratory and/or strictly animal research will not be considered for funding.
• Clinical Translational Potential is the most important review criterion.
• Preliminary data are required.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.